Spero nabs $5.9M DoD award to support SPR206; shares up 4%

• The U.S. Department of Defense (DoD) has awarded $5.9M to Spero Therapeutics (SPRO +4.3%) to support the clinical development of intravenously administered antibiotic SPR206.
• The money will be allocated over a four-year period to cover the costs of Phase 1 pharmacology studies, a 28-day GLP non-human primate toxicology study and microbiological surveillance studies, all of which will support an eventual U.S. marketing application.